stockrow
Wednesday 4 November 2026
Export ASMB’s income statement to Excel — free account
Assembly Biosciences, Inc.
ASMB Healthcare Biotechnology
Assembly Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72.3 million, up 153.5% from fiscal 2024.
- Revenue
- +38.9%
- EPS
- +85.0%
- Free cash flow
- +7.58%
Quarter to June 2026, against a year earlier
19.80
0.12
−0.60%
Follow ASMB
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
8.73 | 7.99 | 6.60 | 6.92 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(21.46) | 40.60 | (21.22) | (33.45) | |
P/B ratio |
1.78 | 2.80 | 2.36 | 1.70 | |
Price to Tangible BV |
2.30 | 3.50 | 2.99 | 1.96 | |
EV/Sales |
2.48 | 4.56 | 3.41 | 2.64 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.65) | (8.03) | (6.10) | (5.14) | |
EV/FCF |
(1.65) | (8.02) | (6.08) | (5.13) | |
Quick Ratio |
4.37 | 5.11 | 6.49 | 13.70 | |
Current Ratio |
4.44 | 5.22 | 6.65 | 13.99 | |
Net Debt/EBITDA |
20.25 | (13.06) | 18.68 | 45.17 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.22 | 0.38 | 0.43 | 0.36 | |
Operating CF/Net income |
1.65 | 0.64 | 2.43 | 4.02 | |
Capex/Depreciation |
0.07 | 0.03 | 0.02 | 0.00 | |
Interest Coverage |
— | — | — | 2.55 | |
Research and Development Expense of Revenue |
153.74% | 40.62% | 181.42% | 111.54% | |
Selling, General and Administrative Expense of Revenue |
47.13% | 12.76% | 57.02% | 35.90% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
15.48% | 3.44% | 13.59% | 18.06% | |
Graham Net Nets |
0.55 | 0.35 | 0.42 | 0.58 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(18.71%) | (5.65%) | (4.65%) | (0.58%) | |
Free Cash Flow Yield |
(17.18%) | (7.12%) | (8.49%) | (7.44%) | |
Revenue per Share |
0.85 | 2.50 | 0.49 | 0.71 | |
Operating CF per Share |
(1.19) | 0.84 | (1.31) | (0.82) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.20) | 0.84 | (1.31) | (0.82) | |
Cash per Share |
18.33 | 14.60 | 13.41 | 16.99 | |
Shareholders Equity per Share |
14.40 | 12.17 | 11.75 | 16.21 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
14.40 | 12.17 | 11.75 | 16.21 | |
Free Cash Flow |
(15.17) | 14.21 | (22.12) | (15.49) | |
Working Capital |
183.43 | 205.77 | 197.62 | 304.53 | |
Capital Expenditures |
(0.04) | (0.02) | (0.02) | 0.00 | |
Net Current Asset Value |
179.51 | 203.71 | 195.72 | 302.80 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.63 | 0.54 | 0.25 | 0.43 | |
Average Payables |
1.51 | 0.88 | 1.00 | 0.96 | |
Average Assets |
170.13 | 188.38 | 167.26 | 205.81 | |
Average Common Equity |
104.35 | 120.06 | 112.87 | 161.87 |
Columns are period end dates · fundamentals updated 26 Oct 2026